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Introduction
HIV-associated nephropathy (HIVAN) is the leading cause of end-stage renal disease in patients with 
HIV-1 infection. While HIVAN involves all portions of the kidney, marked changes in podocyte 
proliferation and dedifferentiation are central to the pathogenesis of this disease. This review focuses 
on identifying the genes and signaling pathways that trigger terminally differentiated quiescent podocytes 
to lose their normal markers of maturity and reenter the cell cycle. The parallels between these alterations 
to malignant transformation are quite striking.
HIVAN and Features of Podocyte Injury
HIV-associated nephropathy (HIVAN) is the leading cause of chronic kidney failure in patients infected 
with HIV (USRDS 2005). The majority of patients with HIVAN are of African descent and HIVAN is 
the third leading cause of end-stage renal disease in African-Americans between the ages of 
20–64 years old (Winston et al. 1998; Schwartz et al. 2005). Typically, HIVAN develops in the setting 
of advanced HIV-1 infection. HIVAN clinically has been characterized by proteinuria, often in the 
nephrotic range, and progressive renal insufﬁ  ciency (Rao et al. 1984; Carbone et al. 1989; Burns et al. 
1997; Winston et al. 1999; Ross and Klotman, 2002). Renal biopsy is required to make the deﬁ  nitive 
diagnosis of HIVAN. Pathologic ﬁ  ndings include microcystic dilatation of renal tubules, collapsing 
focal segmental glomerulosclerosis, and leukocyte inﬁ  ltration and ﬁ  brosis of the renal interstitium 
(D’Agati et al. 1989; D’Agati and Appel, 1998; Ross et al. 2001). Prominent proliferation of renal 
tubular and visceral epithelial cells (podocytes) is a characteristic feature of this disease. Podocytes 
exhibit hypertrophy as well as hyperplasia in HIVAN (D’Agati and Appel, 1997; Lu et al. 2007).
The HIV virus directly infects tubular cells and podocytes leading to the development of HIVAN. 
Not surprisingly, the HIV-1 transgenic mouse (Tg26 mice) model in which renal cells express viral 
proteins has greatly advanced our knowledge of the pathogenesis of HIVAN. The Tg26 mice develop 
proteinuria, progressive renal failure, and renal pathologic ﬁ  ndings identical to HIVAN patients (Dickie 
et al. 1991; Kopp et al. 1992). Reciprocal renal transplant between wild-type and Tg26 mice deﬁ  nitively 
demonstrated the direct link between HIV expression at the kidney to the renal phenotype. HIVAN 
develops in transgenic kidneys transplanted into nontransgenic littermates, but not in normal kidneys 
transplanted into transgenic littermates (Bruggeman et al. 1997). In studies in macaques, investigators 
isolated simian-human immunodeﬁ  ciency virus (SHIV) from glomeruli (Stephens et al. 2000). HIV-1 
RNA has also been detected by RNA in situ hybridization from renal biopsy specimen in HIV-seropositive 
patients (Bruggeman et al. 2000). HIV-1 has been detected in several portions of the nephron, including 
glomerular visceral and parietal epithelial cells and tubular cells (proximal tubule, thick ascending limb 
of loop of Henle, and collecting duct) (Bruggeman et al. 2000; Ross et al. 2001).
Expression of HIV-1 in podocytes is critical to the development of disease pathogenesis. Podocytes 
line the outer aspect of the glomerular basement membrane and serve as the ﬁ  nal barrier to protein loss. 540
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A clear link exists between injury to these cells and 
the development of the HIVAN phenotype. Using 
the Nphs1 promoter in the transgenic mouse model, 
researchers demonstrated that selective podocyte 
expression of  HIV-1 proviral DNA with mutations 
in gag, pol, and env leads to the development of 
massive proteinuria, severe collapsing FSGS, and 
microcystic tubular dilatation (Zhong et al. 2005). 
This study conclusively illustrated that podocyte-
restricted HIV-1 gene expression was sufﬁ  cient for 
development of collapsing glomerulosclerosis.
Unlike other glomerular diseases, HIV-1 
infection triggers both podocyte proliferation and 
dedifferentiation (Lu et al. 2007). Podocytes are 
terminally differentiated post-mitotic cells that, 
under normal conditions, have lost their ability to 
proliferate (Sunamoto et al. 2003). Normal mature 
podocytes remain in a quiescent state and express 
cyclin-dependent kinase (CDK) inhibitors p27 and 
p57 and do not express markers of proliferation 
(cyclin A, cyclin D, and Ki-67) (Barisoni et al. 
2000a; Barisoni et al. 2000b; Shankland and Wolf ). 
The collapse of glomerular capillaries in HIVAN, 
however, occurs in the setting of marked podocyte 
proliferation (Barisoni et al. 1999; Barisoni et al. 
2000a; Barisoni et al. 2000b). This podocyte 
hyperplasia is driven by cell cycle dysregulation. 
In HIVAN, podocytes exhibit increased expression 
of Ki-67, cyclin A, and cyclin D and decreased 
expression of CDK inhibitors p27 and p57 
(Barisoni et al. 2000a; Shankland et al. 2000). The 
net effect of these changes is the reentry of the 
podocyte into the cell cycle, resultant G1 to S phase 
progression and, thus, cell proliferation. In 
subsequent paragraphs, I will present evidence that 
the effects on cell cycle dysregulation have been 
mapped to the expression of the HIV gene nef. 
Indeed, the growth rate of podocytes as measured 
by 
3H thymidine uptake was threefold greater in 
the HIV-1 Tg podocytes compared to nontransgenic 
podocytes (Schwartz et al. 2001).
HIVAN is also accompanied by podocyte 
dedifferentiation. This is characterized by the loss 
of several podocyte differentiation markers, such 
as Wilm’s tumor (WT-1), synaptopodin, podocalyxin, 
common acute lymphoblastic leukemia antigen 
(CALLA), and ezrin (Barisoni et al. 1999; Barisoni 
et al. 2000a; Barisoni et al. 2000b). The loss of 
synaptopodin staining is the most specific for 
HIVAN on immunohistochemical analysis of 
kidney biopsy specimen (Barisoni et al. 1999). 
Dedifferentiation of podocytes appears to be unique 
to HIVAN as these markers are not lost in other 
glomerular diseases associated with the nephrotic 
syndrome (e.g. minimal change disease and 
membranous nephropathy) (Barisoni et al. 1999). 
Podocytes from the HIV Tg26 mouse model exhibit 
a loss of contact inhibition. Additionally, podocytes 
from the HIVAN model demonstrate anchorage 
independent growth of colonies in soft agar in vitro 
(Schwartz et al. 2001; Shah et al. 2006). This is in 
contrast to the normal inhibition of growth of 
immortalized visceral epithelial cells from 
nontransgenic mice upon reaching conﬂ  uence.
Role of nef in the Pathogenesis 
of HIVAN
The HIV-1 genome consists of nine genes: three 
structural genes (gag, pol, env), two regulatory 
genes (tat and rev), and four accessory genes (vif, 
vpr, vpu, and nef ). In HIV-1 infected hosts, the 
27-kDa protein Nef is at an early phase in the viral 
replication cycle and performs several functions 
(Li et al. 2005). These include enhancement of viral 
replication and infectivity, down-regulation of cell 
surface proteins such as CD4 and major histocom-
patibility complex (MHC) class I and II, alteration 
of signal transduction pathways, and modulation 
of endosome trafﬁ  cking pathways (Fackler and 
Baur, 2002; Wei et al. 2003; Li et al. 2005; Zuo 
et al. 2006). In vitro and in vivo data support a 
critical role for Nef in the development of podocyte 
proliferation and dedifferentiation seen in 
HIVAN.
Husain et al. infected conditionally immortalized 
podocytes with HIV-1 proviral constructs with 
premature stop codons inserted into the individual 
env, vif, vpr, vpu, nef, or rev genes (Husain et al. 
2002). Constructs expressing all of the above genes 
led to marked podocyte proliferation and anchorage 
independent growth (growth of colonies in soft 
agar). Additionally, no change in growth parameters 
was observed in cells infected with ∆env, ∆vif, 
∆vpr, ∆vpu, or ∆rev viruses. Proliferation and 
colony formation in soft agar, however, were 
abrogated in podocytes infected with a ∆nef virus. 
Finally, infection with a construct expressing the 
nef gene alone was sufﬁ  cient to induce podocyte 
proliferation, loss of contact inhibition, and 
anchorage independent growth in vitro (Husain 
et al. 2002).
Sunamoto et al. then utilized the same HIV-1 
mutant proviral constructs lacking either env, vif, 541
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vpr, vpu, nef, or rev genes to establish that nef 
induces the dedifferentiation of podocytes in 
HIVAN (Sunamoto et al. 2003). In fact, constructs 
containing nef alone are sufﬁ  cient to suppress the 
markers of podocyte maturity synaptopodin, 
CALLA, and ezrin. Additionally, the presence of 
nef alone also led to decreased expression of the 
CDK inhibitors (p21 and p27) which normally 
prevent mature podocytes from reentering the cell 
cycle (Sunamoto et al. 2003). The presence of nef 
was also sufﬁ  cient to increase the expression of 
the proliferation markers Ki-67, cyclin A, and 
cyclin E (Sunamoto et al. 2003). Only podocytes 
infected with constructs lacking nef demonstrated 
a mature pattern of differentiation markers and lack 
of proliferation. These in vitro data show that Nef 
is the major gene product of HIV-1which drives 
the changes in podocyte dedifferentiation and 
induces reentry into the cell cycle and subsequent 
visceral epithelial cell hyperplasia.
In vivo data has conﬁ  rmed nef ’s critical role in 
the development of the HIVAN phenotype. Hanna 
et al., by mutating HIV genes in transgenic mice, 
demonstrated that nef expression under a human 
CD4 promoter induced interstitial nephritis and 
tubular atrophy and dilatation as seen in HIVAN 
(Hanna et al. 1998). Given the use of the CD4 
promoter, however, nef expression in podocytes 
was likely low and these mice failed to develop 
glomerular disease. A study by Kajiyama et al. 
illustrated the onset of glomerulosclerosis and 
tubular dilatation by 6 weeks of age in transgenic 
mice infected with the HIV-1 provirus with an 
inactivated nef coding sequence (Kajiyama et al. 
2000). When this transgenic line was crossed with 
transgenic mice expressing nef alone, offspring 
developed more severe glomerulosclerosis. Husain 
et al. conducted a subsequent study with the 
transgenic mouse model to examine the role of 
podocyte-speciﬁ  c nef expression in vivo (Husain 
et al. 2005). Nef expressing podocytes had a loss of 
the differentiation marker synaptopodin and 
increased expression of the proliferation marker 
Ki-67 compared to control mice. Nef expressing 
mice, however, failed to develop significant 
proteinuria, had normal histology by light microscopy, 
and had only mild podocyte effacement on electron 
microscopy. These in vivo studies illustrate that nef 
plays a key role in the pathogenesis of glomerular 
and tubulointerstitial injury seen in HIVAN. 
Additionally, there are likely other as of yet 
unknown factors that also contribute to the complex 
phenotype seen in HIVAN. For example, HIV-1 
genes nef and vpr may act synergistically in HIVAN 
pathogenesis. While mice with podocyte-speciﬁ  c 
expression of nef or vpr develop glomerulosclerosis, 
mice expressing both nef and vpr at podocytes 
develop more severe sclerosis (Zuo et al. 2006).
Nef ’s Effect on Downstream 
Signaling Pathways
Given nef ’s intricate involvement in furthering 
proliferation and dedifferentiation of visceral 
epithelial cells at the glomerulus, several studies 
have started to unravel the downstream signaling 
pathways through which nef effects these changes. 
These pathways and identiﬁ  ed biological effects 
nef has on the podocyte are summarized in Figure 1. 
The C-terminal loop of nef mediates viral 
replication and interacts with trafﬁ  cking molecules 
to down-regulate expression of CD4 and MHC I 
(Schwartz et al. 1996; Piguet et al. 1999). Nef 
contains a polyproline helix type II which forms a 
(PxxP)3 sequence cluster (Lee et al. 1996; Geyer 
et al. 2001). This sequence mediates the interaction 
between the SH3 domain of Src family kinases and 
the guanine nucleotide exchange factor Vav (Lee 
et al. 1996; Geyer et al. 2001). Nef also interacts 
with several other cellular proteins, such as protein 
kinase C, mitogen-activated protein kinase 
(MAPK), Raf1, p21-activated kinase (PAK), pI3K, 
Vav1, and Vav2 (Arold and Bauer, 2001).
The Src family kinases are key potentiators of 
cell proliferation, cell to cell adhesion, and cell 
motility (Martin, 2001). These nonreceptor tyrosine 
kinases mediate these effects by leading to 
phosphorylation of proteins, which then in turn 
activate signaling pathways and other protein-
protein interactions. Members of the Src family 
kinases include Src, Hck, Fgr, Lck, Lyn, and Yes. 
Studies have implicated several of these kinases 
in podocyte pathophysiology. For example, Fyn 
binds and phosphorylates nephrin and ∆ Fyn leads 
to the coarsening of podocyte foot processes 
(Lahdenpera et al. 2003; Verma et al. 2003).
Src activation by Nef leads to activation of the 
transcription factor signal transducer and activator 
of transcription 3 (Stat3) (Akira, 2000). Phosphorylated 
Stat3 dimerizes, moves into the nucleus, and serves 
as a transcription factor for genes involved in cell 
growth, differentiation, and apoptosis. Stat3 
activation has been demonstrated in both the 
developing kidney and in renal cell carcinoma 542
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Figure 1. Nef binds to Src kinase, c-Raf, p21-activated kinase (PAK2), and the guanine nucleotide exchange factor Vav. The nef domains 
that serve as binding motifs for these interactions are outlined in this ﬁ  gure. Via a Src-dependent pathway, nef activates both the Stat3 and 
Ras-cRaf mitogen-activated protein kinase (MAPK) 1, 2 pathways. Activation of these pathways leads to podocyte proliferation and 
dedifferentiation. Nef, via its R105106 domain, activates PAK2 and mediates alterations in the actin cytoskeleton in podocytes.
(Barasch et al. 1999; Horiguchi et al. 2002). Stat3, 
after activation by Src in hematopoetic cells, causes 
upregulation of the cell proliferation marker cyclin 
E (Odajima et al. 2000).
Activation and signaling of the MAPK family 
plays a role in mitogenesis and cell differentiation. 
Nef can activate this downstream signaling pathway 
via Raf and Src activation (Tian et al. 2000). MAPK 
signaling is upregulated in several kidney diseases, 
such as rodent models of proliferative anti-glomerular 
glomerulonephritis, ischemia-reperfusion injury, 
renal cell carcinoma, and autosomal-dominant poly-
cystic kidney disease (Oka et al. 1995; Bokemeyer 
et al. 1997; Nagao et al. 2003; Yang et al. 2003).
He et al. completed studies in immortalized and 
differentiated podocytes to establish a link between 
nef and downstream signaling pathways in vitro 
(He et al. 2004). Podocytes infected with nef have 
increased Src kinase activity and Stat3 phosphorylation 
compared to controls. Use of PP2, an inhibitor of 
Src kinase phosphorylation, blocks both Src kinase 
and Stat3 phosphorylation and, thus, conﬁ  rms the 
conﬁ  guration of the downstream signaling pathway. 
Expression of nef in podocytes also activates the 
Ras-c-Raf-MAPK1, 2 pathway (He et al. 2004). 
A dominant negative mutant form of Src kinase 
(Src-DN) abrogated nef-induced phosphorylation 
of Stat3 and MAPK1, 2. Src-DN inhibited podocyte 
expression of the proliferation marker cyclin E and 
restored markers of mature podocyte differentiation. 
Therefore, this dominant negative mutant data 
established Src kinase as an upstream activator of 543
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both Stat3 and MAPK1, 2 in mediating nef-induced 
podocyte phenotypic changes of proliferation and 
dedifferentiation (He et al. 2004). Use of small 
interference RNA to reduce nef expression 
decreased Stat3 and MAPK1, 2 phosphorylation, 
cyclin E expression, and podocyte cell proliferation 
(He et al. 2004). Finally, inhibition of MAPK1, 
2 phosphorylation and a dominant negative mutant 
of Stat3 partially reversed the effects of nef on the 
podocyte proliferation and dedifferentiation (He 
et al. 2004). The absence of a complete phenotypic 
reversal with Stat3 and MAPK1, 2 inhibition 
indicate that yet undiscovered pathways downstream 
from Nef or Stat3 may also contribute to the 
changes at the podocyte in HIVAN.
Two Nef domains (PxxP and R105R106) are binding 
sites for the SH3 domain of the Src kinase family 
and PAK2. Using immortalized murine podocytes, 
mutations of Nef in the PxxP region have been 
shown to have the following effects in vitro: inhibi-
tion of Stat3 and MAPK1, 2 phosphorylation, reduc-
tion of cyclin E expression, restoration of 
synaptopodin expression, and reversal of Nef-induced 
cell proliferation (He et al. 2004). While mutation 
of the R105R106 domain did increase synaptopodin 
expression, mutation at this site failed to change 
phosphorylation of Stat3 or MAPK1, 2 and only 
minimally decreased cell proliferation (He et al. 
2004). The data presented by He et al. illustrate that 
the PxxP motif of Nef is the site responsible for 
Nef-induced Stat3 and MAPK1, 2 phosphorylation 
and the downstream cellular signaling effects 
leading to podocyte proliferation and dedifferentiation. 
While the R105R106 motif may exert some of Nef’s 
effects leading to the HIVAN phenotype in 
podocytes, it is likely through a signaling cascade 
independent of Stat3 and MAPK1, 2 activation. 
A summary of known pathways of nef signaling and 
its downstream effectors is presented in Figure 1.
We conﬁ  rmed these signaling pathways are 
critical to mediating Nef’s effect on the HIVAN 
phenotype in vitro. Immunostaining for phospho-
Stat3 is markedly elevated in the glomeruli of 
transgenic mice with podocyte-speciﬁ  c nef expres-
sion compared to control littermates (Husain et al. 
2005). Also, in human kidney biopsy specimen 
from patients with HIVAN, immunostaining dem-
onstrated increased staining of phospho-Stat3 and 
phospho-MAPK1, 2 compared to controls. The 
control patients in this experiment included HIV-1 
patients without HIVAN and non-HIV infected 
patients with minimal change disease, idiopathic 
collapsing FSGS, or classic FSGS (He et al. 2004). 
Additionally, in the Tg26 mouse, mutating the 
PxxP SH3-binding domain of nef generated mice 
that no longer exhibited the HIVAN phenotype 
(Omori et al. 2000). This study provided further in 
vivo evidence that nef induces the myriad of renal 
cortical abnormalities that characterize the HIVAN 
phenotype via activation of the Src family of tyro-
sine kinases.
Vincent et al. have proposed that nef interaction 
and activation of PAK2 in the murine model con-
tributes to the HIVAN phenotype (Renkema et al. 
1999; Arora et al. 2000; Vincent et al. 2006). Acti-
vated PAK has been proposed to play a role in cell 
cytoskeletal reorganization, MAPK signaling cas-
cades, pro and anti-apoptotic effects, and virion 
infectivity (Wiskerchen and Cheng-Meyer, 1996; 
Bagrodia et al. 1997; Rudel and Bokoch, 1997; 
Rudel et al. 1998; Sells et al. 1999; Schurmann 
et al. 2000; Jakobi et al. 2001). HIV transgenic 
mice that express nef alleles but lacking the Nef—
PAK2 association do not exhibit kidney disease. 
This identiﬁ  es Nef binding and activating PAK2 
as critical to the development of HIVAN. Activa-
tion of PAK2 alone, however, is not sufﬁ  cient to 
develop kidney disease. Transgenic mice express-
ing nef mutants that were able to bind and activate 
PAK2 failed to exhibit kidney disease (Vincent 
et al. 2006).
Conclusion
HIVAN is characterized by marked proteinuria, 
renal insufﬁ  ciency and characteristic pathologic 
changes on kidney biopsy. Marked podocyte 
proliferation and dedifferentiation occurs within 
the collapsing glomerulopathy found in HIVAN. 
These podocyte changes are not seen in other 
glomerular diseases. HIV-1 Nef is the critical 
protein mediating reentry of podocytes into the cell 
cycle and down-regulation of mature podocyte 
differentiation markers. In vitro and in vivo 
evidence indicates that Nef induces these changes 
in the podocyte via Src kinase-dependent activation 
of Stat3 and MAPK1,2 signaling pathways. 
Additionally, Nef interaction with PAK2 may 
contribute to some of the features of the HIVAN 
phenotype. There are still several downstream 
targets that have yet to be identified which 
potentiate the development of podocyte proliferation 
and dedifferentiation. Evidence also indicates that 
Nef may activate other pathways, in addition to 544
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Stat3 and MAPK1, 2, as part of the pathogenesis 
of HIVAN. Continued studies are needed to identify 
downstream effectors of Nef and therapeutic inter-
ventions that may abrogate the activity of these 
signaling pathways.
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